Notice of Annual General Meeting 2024
Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 22 May...
Read moreLatest News
Category: News
Q1 2024 Revenue and Business Update
Telix today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1...
Read more
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or...
Read more
TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)
Telix today welcomes updated guidelines from the European Association of Urology (EAU) that for the first time include TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab) as an emerging technology for the management of renal...
Read more
Telix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform
Telix, today announces the completion of the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals...
Read more
Telix Completes Acquisition of IsoTherapeutics
Telix today announces the completion of the acquisition of IsoTherapeutics. IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in...
Read more
Telix GM 2024
Telix's 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and...
Read more
Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological...
Read more
World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature...
Read more
First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
Telix today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...
Read more